PT  - JOURNAL ARTICLE
AU  - Jason A. Sprowl
AU  - Alex Sparreboom
TI  - Uptake Carriers and Oncology Drug Safety
AID  - 10.1124/dmd.113.055806
DP  - 2014 Apr 01
TA  - Drug Metabolism and Disposition
PG  - 611--622
VI  - 42
IP  - 4
4099  - http://dmd.aspetjournals.org/content/42/4/611.short
4100  - http://dmd.aspetjournals.org/content/42/4/611.full
SO  - Drug Metab Dispos2014 Apr 01; 42
AB  - Members of the solute carrier (SLC) family of transporters are responsible for the cellular influx of a broad range of endogenous compounds and xenobiotics in multiple tissues. Many of these transporters are highly expressed in the gastrointestinal tract, liver, and kidney and are considered to be of particular importance in governing drug absorption, elimination, and cellular sensitivity of specific organs to a wide variety of oncology drugs. Although the majority of studies on the interaction of oncology drugs with SLC have been restricted to the use of exploratory in vitro model systems, emerging evidence suggests that several SLCs, including OCT2 and OATP1B1, contribute to clinically important phenotypes associated with those agents. Recent literature has indicated that modulation of SLC activity may result in drug-drug interactions, and genetic polymorphisms in SLC genes have been described that can affect the handling of substrates. Alteration of SLC function by either of these mechanisms has been demonstrated to contribute to interindividual variability in the pharmacokinetics and toxicity associated with several oncology drugs. In this report, we provide an update on this rapidly emerging field.